share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  05/08 09:28
Moomoo AI 已提取核心訊息
On May 7, 2024, ProSomnus, Inc., a medical technology company, filed for Chapter 11 bankruptcy and entered into a Restructuring Support Agreement (RSA) with its affiliates, subsidiaries, and certain note holders. The RSA outlines a voluntary restructuring plan, which includes a debtor-in-possession credit facility of $13 million, provided by sponsoring Senior and Subordinated Noteholders, to support the company's operations during the restructuring process. The plan also proposes a new-money equity capital raise of at least $9 million. ProSomnus aims to reorganize its equity structure, with new common equity to be distributed to Subordinated Secured Noteholders, diluting existing equity holders who are expected to experience a complete loss. The company's common stock and warrants were delisted from Nasdaq on April 24, 2024, and are now traded over-the-counter. The restructuring is subject to court approval, with the company operating as a debtor in possession and seeking to continue business operations as usual. The company cautions that trading in its securities is highly speculative and poses substantial risks during the Chapter 11 process.
On May 7, 2024, ProSomnus, Inc., a medical technology company, filed for Chapter 11 bankruptcy and entered into a Restructuring Support Agreement (RSA) with its affiliates, subsidiaries, and certain note holders. The RSA outlines a voluntary restructuring plan, which includes a debtor-in-possession credit facility of $13 million, provided by sponsoring Senior and Subordinated Noteholders, to support the company's operations during the restructuring process. The plan also proposes a new-money equity capital raise of at least $9 million. ProSomnus aims to reorganize its equity structure, with new common equity to be distributed to Subordinated Secured Noteholders, diluting existing equity holders who are expected to experience a complete loss. The company's common stock and warrants were delisted from Nasdaq on April 24, 2024, and are now traded over-the-counter. The restructuring is subject to court approval, with the company operating as a debtor in possession and seeking to continue business operations as usual. The company cautions that trading in its securities is highly speculative and poses substantial risks during the Chapter 11 process.
2024年5月7日，醫療技術公司ProSomnus, Inc. 申請了第11章破產，並與其關聯公司、子公司和某些票據持有人簽訂了重組支持協議（RSA）。RSA概述了一項自願重組計劃，其中包括由擔保的優先和次級票據持有人提供的1300萬美元債務人持股信貸額度，以支持公司在重組過程中的運營。該計劃還提議籌集至少900萬美元的新資金股權。ProsomNUS旨在重組其股權結構，向次級有擔保票據持有人分配新的普通股，從而稀釋預計將遭受全部虧損的現有股權持有人。該公司的普通股和認股權證於2024年4月24日從納斯達克退市，現在在場外交易。重組須經法院批准，公司以債務人的身份經營，並尋求照常經營業務。該公司警告說，其證券交易具有高度投機性，在第11章過程中構成重大風險。
2024年5月7日，醫療技術公司ProSomnus, Inc. 申請了第11章破產，並與其關聯公司、子公司和某些票據持有人簽訂了重組支持協議（RSA）。RSA概述了一項自願重組計劃，其中包括由擔保的優先和次級票據持有人提供的1300萬美元債務人持股信貸額度，以支持公司在重組過程中的運營。該計劃還提議籌集至少900萬美元的新資金股權。ProsomNUS旨在重組其股權結構，向次級有擔保票據持有人分配新的普通股，從而稀釋預計將遭受全部虧損的現有股權持有人。該公司的普通股和認股權證於2024年4月24日從納斯達克退市，現在在場外交易。重組須經法院批准，公司以債務人的身份經營，並尋求照常經營業務。該公司警告說，其證券交易具有高度投機性，在第11章過程中構成重大風險。
有用
沒用

該公告為獨立文件：

獨立文件1

獨立文件2

獨立文件3

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息